Fabre-Kramer Submits NDA Amendment for Exxua ™ for Treatment of Major Depressive Disorder

HOUSTON, Jan. 4, 2023 /PRNewswire/— Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug Administration (FDA) for its novel mechanism antidepressant...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news